{"filing":{"accession_number":"0001193125-26-337977","cik":"0001817713","ticker":"JANX","company_name":"Janux Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"janx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-20260806.htm"},"events":[{"id":25609,"run_id":23243,"accession_number":"0001193125-26-337977","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026. The press release reports key financial metrics including cash position ($970.9 million), R\u0026D expenses ($31.0 million for Q2), G\u0026A expenses ($11.0 million for Q2), and net loss ($22.0 million for Q2), along with condensed balance sheets and statements of operations. The disclosure is material to investors assessing the company's financial condition and cash runway as a clinical-stage biopharmaceutical company.","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26489,"accession_number":"0001193125-26-337977","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026. The press release reports key financial metrics including cash position ($970.9 million), R\u0026D expenses ($31.0 million for Q2), G\u0026A expenses ($11.0 million for Q2), and net loss ($22.0 million for Q2), along with condensed balance sheets and statements of operations. The disclosure is material to investors assessing the company's financial condition and cash runway as a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:47.221904+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26489,"accession_number":"0001193125-26-337977","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026. The press release reports key financial metrics including cash position ($970.9 million), R\u0026D expenses ($31.0 million for Q2), G\u0026A expenses ($11.0 million for Q2), and net loss ($22.0 million for Q2), along with condensed balance sheets and statements of operations. The disclosure is material to investors assessing the company's financial condition and cash runway as a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:47.221904+00:00","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-08-06"}]}